Saturday 17 October 2026
Export BAX’s income statement to Excel — free account
Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
25.33
0.43
−1.67%
Follow BAX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.96 | 0.76 | 0.87 | 1.06 | |
P/FCF ratio |
13.52 | 11.97 | 29.53 | 47.97 | |
P/Operating CF |
38.68 | 40.62 | 16.79 | 49.38 | |
P/B ratio |
1.78 | 1.44 | 1.61 | 1.62 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.60 | 1.42 | 1.54 | 1.77 | |
EV/EBITDA |
12.61 | 11.13 | 11.96 | 13.46 | |
EV/Operating CF |
13.90 | 12.87 | 20.49 | 26.01 | |
EV/FCF |
22.49 | 22.27 | 52.15 | 79.84 | |
Quick Ratio |
1.12 | 1.01 | 1.29 | 0.93 | |
Current Ratio |
1.95 | 1.85 | 2.31 | 1.84 | |
Net Debt/EBITDA |
16.03 | 24.57 | 26.26 | 19.01 | |
Debt/Assets |
47.79% | 47.68% | 47.25% | 45.10% | |
Debt/Equity |
1.53 | 1.57 | 1.55 | 1.32 | |
Asset Turnover |
0.56 | 0.55 | 0.49 | 0.46 | |
Operating CF/Net income |
2.26 | (14.20) | (0.52) | (5.15) | |
Capex/Depreciation |
(0.49) | (0.58) | (0.14) | (0.47) | |
Interest Coverage |
3.39 | 1.00 | (12.57) | 2.97 | |
Research and Development Expense of Revenue |
4.36% | 5.15% | 4.24% | 4.16% | |
Selling, General and Administrative Expense of Revenue |
24.83% | 26.95% | 25.59% | 24.97% | |
Intangible Assets out of Total Assets |
0.45 | 0.46 | 0.46 | 0.48 | |
Share Based Compensation of Revenue |
1.11% | 0.37% | 1.24% | 1.23% | |
Graham Net Nets |
(0.60) | (0.81) | (0.72) | (0.59) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.71%) | (12.68%) | (9.68%) | (2.90%) | |
Free Cash Flow Yield |
7.39% | 8.36% | 3.39% | 2.08% | |
Revenue per Share |
5.73 | 5.24 | 5.80 | 5.52 | |
Operating CF per Share |
0.55 | 0.41 | 1.14 | 0.46 | |
Capex per Share |
(0.22) | (0.27) | (0.27) | (0.22) | |
Free Cash Flow per Share |
0.33 | 0.15 | 0.87 | 0.25 | |
Cash per Share |
4.16 | 3.92 | 3.83 | 3.36 | |
Shareholders Equity per Share |
11.95 | 11.68 | 11.89 | 14.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.95 | 11.68 | 11.89 | 14.04 | |
Free Cash Flow |
169.00 | 76.00 | 444.00 | 126.00 | |
Working Capital |
3,398.00 | 3,154.00 | 3,902.00 | 3,158.00 | |
Capital Expenditures |
(116.00) | (137.00) | (140.00) | (111.00) | |
Net Current Asset Value |
(6,623.00) | (6,983.00) | (7,081.00) | (6,920.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,814.50 | 1,672.00 | 1,770.00 | 1,753.00 | |
Average Payables |
1,014.50 | 1,024.50 | 983.50 | 897.00 | |
Average Inventory |
2,321.50 | 2,243.00 | 2,139.00 | 2,281.50 | |
Average Assets |
20,418.50 | 20,575.00 | 22,918.50 | 23,871.50 | |
Average Common Equity |
6,736.00 | 6,535.00 | 6,563.00 | 7,578.00 |
Columns are period end dates